natgillin/translations-raw huggingface dataset:
If you have used certain other medicines in the last 4 weeks, in particular for epilepsy, tuberculosis, HIV infection or herbal medicines containing St. John´s wort (see leaflet), ellaOne may work less effectively. 
Ako ste uzimali neke druge lijekove u posljednja 4 tjedna, posebice za epilepsiju, tuberkulozu, infekciju HIV-om ili biljne pripravke koji sadrže gospinu travu (vidjeti uputu o lijeku), ellaOne može imati slabiji učinak.
If vomiting occurs within 3 hours of the tablet intake, another tablet should be taken. 
Javi li se povraćanje unutar 3 sata nakon uzimanja tablete, treba uzeti još jednu tabletu.
Such high doses were well-tolerated; however, these women had a shortened menstrual cycle (uterine bleeding occurring 2-3 days earlier than would be expected) and in some women, the duration of bleeding was prolonged, although not excessive in amount (spotting). 
Međutim, kod tih je žena došlo do skraćenog menstrualnog ciklusa (krvarenje iz maternice pojavljivalo se 2-3 dana ranije nego očekivano), a u nekih se žena krvarenje produljilo, iako ne u velikoj količini (krvavi iscjedak).
When the data from the two trials were combined via meta- analysis, the risk of pregnancy with ulipristal acetate was significantly reduced compared to levonorgestrel (p=0.046). 
Meta-analiza kombiniranih podataka dva ispitivanja pokazala je značajno smanjen rizik trudnoće s ulipristalacetatom u usporedbi s levonorgestrelom (p=0,046).
Diarrhoea Dry mouth Dyspepsia Flatulence 
Proljev Suha usta Dispepsija Flatulencija
Do not use this medicine after the expiry date which is on the carton and on the blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza EXP.
The patient should be informed not to drive or use machines if they are experiencing such symptoms (see section 4.8). 
Bolesnice treba upozoriti da u slučaju pojave takvih simptoma ne upravljaju vozilima ili strojevima (vidjeti dio 4.8).
This medicine is suitable for any woman of childbearing age, including adolescents. 
Ovaj je lijek pogodan za sve žene u dobi u kojoj mogu zatrudnjeti, uključujući adolescentice.
This medicine will not protect you against HIV infection or any other sexually transmitted diseases (e.g. chlamydia, genital herpes, genital warts, gonorrhoea, hepatitis B and syphilis). 
Ovaj Vas lijek neće zaštititi od infekcije HIV-om ili drugih spolno prenosivih bolesti (npr. klamidije, genitalnog herpesa, kondiloma, gonoreje, hepatitisa B i sifilisa).
In vitro data indicate that ulipristal acetate and its active metabolite do not significantly inhibit CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4, at clinically relevant concentrations. 
In vitro podaci pokazuju da ulipristalacetat i njegov aktivni metabolit u klinički značajnim koncentracijama bitno ne inhibiraju CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1 i 3A4.
Excipients with known effect Each tablet contains 237 mg of lactose (as monohydrate). 
Pomoćne tvari s poznatim učinkom Jedna tableta sadrži 237 mg laktoze (u obliku hidrata).
Always take this medicine exactly as described in this leaflet or as your pharmacist, doctor or other healthcare professional has told you. 
Uvijek uzmite ovaj lijek točno onako kako je opisano u ovoj uputi ili kako Vam je rekao Vaš ljekarnik, liječnik ili drugi zdravstveni djelatnik.
Odds ratio [95% CI] of pregnancy risk, ulipristal acetate vs levonorgestrel2 
Omjer šansi [95% CI] za pojavu trudnoće: ulipristalacetat naspram levonorgestrela2
Some symptoms such as breast tenderness and abdominal (stomach) pain, throwing up (vomiting), feeling sick (nausea) are also possible signs of pregnancy. 
Neki simptomi kao što su osjetljivost dojki, bol u trbuhu, povraćanje i mučnina također mogu biti znakovi trudnoće.
Potential for ulipristal acetate to affect other medicinal products 
Mogućnost utjecaja ulipristalacetata na druge lijekove
In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI. 
Sve žene hitnu kontracepciju trebaju uzeti što ranije nakon nezaštićenog snošaja, bez obzira na tjelesnu težinu ili ITM.
LABORATOIRE HRA PHARMA 200 avenue de Paris 92320 CHATILLON France 
LABORATOIRE HRA PHARMA 200 avenue de Paris 92320 CHATILLON Francuska
The most commonly reported adverse reactions were headache, nausea, abdominal pain and dysmenorrhea. 
Najčešće prijavljene nuspojave bile su glavobolja, mučnina, bolovi u abdomenu i dismenoreja.
Results from two independent randomised controlled trials (see Table) showed the efficacy of ulipristal acetate to be non-inferior to that of levonorgestrel in women who presented for emergency contraception between 0 and 72 hours after unprotected intercourse or contraceptive failure. 
Rezultati dva neovisna randomizirana kontrolirana ispitivanja (pogledati tablicu) pokazuju kako djelotvornost ulipristalacetata nije inferiorna djelotvornosti levonorgestrela u žena koje su podvrgnute hitnoj kontracepciji između 0 i 72 sata nakon nezaštićenog snošaja ili zatajenja kontracepcijske metode.
This medicine may make regular hormonal contraceptives, like pills and patches, temporarily less effective. 
Ovaj lijek može privremeno smanjiti učinkovitost redovnih hormonskih kontraceptiva kao što su kontracepcijske tablete i flasteri.
During this time it is recommended to express and discard the breast milk in order to stimulate lactation. 
Za to vrijeme preporučuje se izdajati i odbaciti izdojeno majčino mlijeko kako bi se potaknula laktacija.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1.
The clinical relevance of this interaction for single dose administration of ulipristal acetate as emergency contraception is not known. 
Klinički značaj te interakcije na primjenu pojedinačne doze ulipristalacetata kao hitnog kontraceptiva nije poznat.
No data are available on the efficacy of ulipristal acetate when taken more than 120 hours (5 days) after unprotected intercourse. 
Nema podataka o djelotvornosti ulipristalacetata kada se uzme više od 120 sati (5 dana) nakon nezaštićenog snošaja.
*Symptom which could also be related to an undiagnosed pregnancy (or related complications) Adolescents: the safety profile observed in women less than 18 years old in studies and post-marketing is similar to the safety profile in adults during the phase III program (see section 4.2). 
*Simptomi koji mogu također biti povezani s neutvrđenom trudnoćom (ili povezanim komplikacijama) Adolescenti: sigurnosni profil opažen u žena mlađih od 18 godina tijekom ispitivanja i nakon stavljanja lijeka u promet, sličan je sigurnosnom profilu u odraslih žena tijekom ispitivanja faze III (vidjeti dio 4.2).
If you become pregnant despite taking this medicine, there is no evidence that it will affect your pregnancy. 
Ako zatrudnite iako ste uzeli ovaj lijek, nema dokaza da će on utjecati na trudnoću.
P-glycoprotein (P-gp) substrates 
Supstrati P-glikoproteina (P-gp)
Before taking this medicine, if your period is late, tell your pharmacist, doctor or other healthcare professional, or do a pregnancy test in order to make sure you are not already pregnant (see section “Warning and precautions”). 
Ako Vam menstruacija kasni, prije nego uzmete ovaj lijek, obratite se ljekarniku, liječniku ili drugom zdravstvenom djelatniku ili napravite test na trudnoću kako biste bili sigurni da već niste trudni (pogledajte dio „Upozorenja i mjere opreza”).
17, rue de Pontoise 95520 Osny France 
17, rue de Pontoise 95520 Osny Francuska
Pregnancy rate (%) within 72h of unprotected intercourse or contraceptive failure2 
Stopa trudnoće (%) unutar 72 sata od nezaštićenog snošaja ili zatajenja kontracepcijske metodeP2
Each carton contains one blister. 
Svaka kutija sadrži jedan blister.
Similar results were obtained for the active mono-demethylated metabolite. 
Slični rezultati dobiveni su i s aktivnim monodemetiliranim metabolitom.
In the absence of specific studies, ulipristal acetate is not recommended. 
Zbog nedostatka odgovarajućih ispitivanja, primjena ulipristalacetata se ne preporučuje.
In all women, emergency contraception should be taken as soon as possible after unprotected intercourse. 
Sve žene hitnu kontracepciju trebaju uzeti što prije nakon nezaštićenog spolnog odnosa.
Other contraceptives and ellaOne 
Drugi kontraceptivi i ellaOne
What you need to know before you take ellaOne Do not take ellaOne 
Što morate znati prije nego uzmete ellaOne
However, if your period is more than 7 days late; if it is unusually light or unusually heavy; or if you experience symptoms such as abdominal (stomach) pain, breast tenderness, vomiting or nausea, you may be pregnant. 
Međutim, ako Vaša menstruacija kasni više od 7 dana, ako je neuobičajeno oskudna ili neuobičajeno obilna, ili ako imate simptome kao što su bol u trbuhu, osjetljivost dojki, povraćanje ili mučnina, možda ste trudni.
Thus, administration of ulipristal acetate is unlikely to alter the clearance of medicinal products that are metabolised by these enzymes. 
Prema tome, nije vjerojatno da primjena ulipristalacetata mijenja klirens lijekova koji se metaboliziraju tim enzimima.
If you are already pregnant it will not interrupt an existing pregnancy. 
Ako ste već trudni, neće prekinuti postojeću trudnoću.
Ulipristal acetate also has high affinity for the glucocorticoid receptor and in vivo, in animals, antiglucocorticoid effects have been observed. 
Ulipristalacetat također ima visoki afinitet prema glukokortikoidnom receptoru te je u uvjetima in vivo, u pokusnih životinja opažen antiglukokortikoidni učinak.
In case the next menstrual period is more than 7 days late, if the menstrual period is abnormal in character or if there are symptoms suggestive of pregnancy or in case of doubt, a pregnancy test should be performed. 
U slučaju kašnjenja sljedeće menstruacije više od 7 dana, ako je menstruacija svojim značajkama abnormalna ili ako postoje simptomi koji ukazuju na trudnoću ili postoji sumnja na trudnoću, treba napraviti test na trudnoću.
Ulipristal acetate is highly bound (>98%) to plasma proteins, including albumin, alpha-l-acid glycoprotein, and high density lipoprotein. 
Ulipristalacetat se u visokom postotku (>98%) veže na proteine plazme, uključujući albumin, alfa-1kiseli glikoprotein i lipoprotein velike gustoće.
In vitro data indicate that ulipristal acetate may be an inhibitor of BCRP (Breast Cancer Resistance Protein) transporters at the intestinal level. 
In vitro podaci ukazuju da ulipristalacetat može biti inhibitor prijenosnika proteina rezistencije raka dojke na lijekove (BCRP) u crijevima.
LABORATOIRE HRA PHARMA 200 avenue de Paris 
Nositelj odobrenja za stavljanje lijeka u promet LABORATOIRE HRA PHARMA 200 avenue de Paris
Experience with ulipristal acetate overdose is limited. 
Iskustvo s predoziranjem ulipristalacetata je ograničeno.
The effects of CYP3A4 inhibitors are unlikely to have any clinical consequences. 
Nije vjerojatno da učinci CYP3A4 inhibitora imaju ikakve kliničke posljedice.
No pharmacokinetic studies with ulipristal acetate have been performed in females with impaired renal or hepatic function. 
Farmakokinetička ispitivanja s ulipristalacetatom nisu provedena u žena s poremećajem funkcije bubrega ili jetre.
In any case, women should be advised to adopt a regular method of contraception. 
Žene je uvijek potrebno savjetovati o primjeni jedne od metoda redovne kontracepcije.
Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days in 78.6% of cases (p<0.005 vs. levonorgestrel and vs. placebo) 
Farmakodinamički podaci pokazuju da čak i kada se uzme neposredno prije ovulacije (nakon što se razina LH već počela povećavati) ulipristalacetat može odgoditi prsnuće folikula za najmanje 5 dana u 78,6% slučajeva (p<0,005 naspram levonorgestrela i naspram placeba) (vidjeti tablicu).
Other medicines and ellaOne 
Drugi lijekovi i ellaOne
When your period is late or when you have symptoms of pregnancy (heavy breasts, morning sickness) you should consult a doctor or other healthcare professional before taking the tablet. 
Ako Vaša menstruacija kasni ili ako imate simptome trudnoće (osjećaj težine u dojkama, jutarnje mučnine), morate se obratiti liječniku ili drugom zdravstvenom djelatniku prije uzimanja tablete.
- if you are allergic to ulipristal acetate or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati ellaOne − ako ste alergični na ulipristalacetat ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time. 
Ako se podnošenje periodičkog izvješća o neškodljivosti (PSUR) podudara s nadopunama Plana (RMP), oba dokumenta mogu biti podnesena istodobno.
Although the use of ulipristal acetate for emergency contraception does not contraindicate the continued use of regular hormonal contraception, ellaOne may reduce its contraceptive action (see section 4.5). 
Iako pri uzimanju ulipristalacetata kao hitne kontracepcije nije kontraindicirana daljnja primjena redovne hormonske kontracepcije, ellaOne može smanjiti njezino kontracepcijsko djelovanje (vidjeti dio 4.5).
Nausea* 
Mučnina*
IUD (intrauterine device) 
Intrauterini uložak (IUD)
Two trials provide efficacy data on ellaOne used up to 120 hours after unprotected intercourse. 
Dva ispitivanja pružaju rezultate djelotvornosti ellaOne primjenjene do 120 sati nakon nezaštićenog snošaja.
There is more information about contraception at the end of this leaflet. 
Na kraju ove upute možete pronaći više informacija o kontracepciji.
The adverse reactions reported in the phase III program of 2,637 women are provided in the table below. 
U tablici niže prikazane su nuspojave prijavljene tijekom kliničkog programa faze III koji je obuhvatio 2637 žena.
Results in vivo with the P-gp substrate fexofenadine were inconclusive. 
In vivo rezultati s P-gp supstratom feksofenadinom su bili neuvjerljivi.
Because ulipristal acetate binds to the progesterone receptor with high affinity, it may interfere with the action of progestogen-containing medicinal products: - Contraceptive action of combined hormonal contraceptives and progestogen-only contraception may be reduced - Concomitant use of ulipristal acetate and emergency contraception containing levonorgestrel is not recommended (see section 4.4). 
Kako se s visokim afinitetom veže na receptore za progesteron, ulipristalacetat može utjecati na djelovanje lijekova koji sadrže progestagene: - kontracepcijsko djelovanje kombiniranih hormonskih kontraceptiva i kontracepcije koja sadrži samo progestagen može biti smanjeno - istodobna primjena ulipristalacetata i hitne kontracepcije koja sadrži levonorgestrel se ne preporučuje (vidjeti dio 4.4).
In addition, the second comparative trial described above also provides data on 100 women treated with ulipristal acetate from 72 to 120 hours after unprotected intercourse, in whom no pregnancies were observed. 
Dodatno, drugim komparativnim ispitivanjem opisanim gore također su dobiveni podaci o 100 žena koje su uzele ulipristalacetat između 72 i 120 sati nakon nezaštićenog snošaja u kojih nisu opažene trudnoće.
Adolescents: the safety profile observed in women less than 18 years old in studies and post-marketing is similar to the safety profile in adults during the phase III program (see section 4.2). 
Adolescenti: sigurnosni profil opažen u žena mlađih od 18 godina tijekom ispitivanja i nakon stavljanja lijeka u promet, sličan je sigurnosnom profilu u odraslih žena tijekom ispitivanja faze III (vidjeti dio 4.2).
Medicinal products affecting gastric pH 
Lijekovi koji utječu na pH želuca
Ulipristal acetate is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant. 
Ulipristalacetat nije namijenjen uporabi tijekom trudnoće i ne smiju ga uzimati žene koje sumnjaju ili znaju da su trudne.
Ulipristal acetate is extensively metabolised to mono-demethylated, di-demethylated and hydroxylated metabolites. 
Ulipristalacetat se opsežno metabolizira u mono-demetilirane, di-demetilirane i hidroksilirane metabolite.
Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor. 
Ulipristalacetat je peroralni sintetski selektivni modulator progesteronskih receptora koji djeluje vežući se visokim afinitetom na humani progesteronski receptor.
PHARMACEUTICAL PARTICULARS 6.1 List of excipients 
6. FARMACEUTSKI PODACI 6.1 Popis pomoćnih tvari
ellaOne is available in a carton containing one blister of 1 tablet. 
ellaOne je dostupna u kutiji koja sadrži jedan blister s 1 tabletom.
Post-marketing experience: the adverse reactions spontaneously reported in post-marketing experience were similar in nature and frequency to the safety profile described during the phase III program. 
Iskustvo nakon stavljanja lijeka u promet: spontano prijavljene nuspojave tijekom uporabe nakon stavljanja lijeka u promet bile su po svojoj prirodi i učestalosti slične sigurnosnom profilu opisanom tijekom ispitivanja faze III.
Limited and inconclusive data suggest that there may be reduced efficacy of ellaOne with increasing body weight or body mass index (BMI) (see section 5.1). 
Ograničeni podaci koji ne dopuštaju donošenje konačnih zaključaka ukazuju na to da se djelotvornost ellaOne može smanjivati s porastom tjelesne težine ili indeksa tjelesne mase (ITM) (vidjeti dio 5.1).
Liek, s.r.o. 
Slovenská republika Liek, s.r.o.
Therefore, if a woman wishes to start or continue using hormonal contraception, she can do so after using ellaOne, however, she should be advised to use a reliable barrier method until the next menstrual period. 
Stoga žena nakon uzimanja ellaOne može početi ili nastaviti koristiti hormonsku kontracepciju, međutim, treba je savjetovati da do sljedeće menstruacije koristi pouzdano mehaničko kontracepcijsko sredstvo.
If a woman's menstrual period is late or in case of symptoms of pregnancy, pregnancy should be excluded before the tablet is administered. 
Ako ženi kasni menstruacija ili u slučaju simptoma trudnoće, prije primjene tablete potrebno je isključiti trudnoću.
- CYP3A4 inhibitors 
- Inhibitori CYP3A4
- The other ingredients are lactose monohydrate, povidone, croscarmellose sodium, magnesium stearate. 
• Drugi sastojci su laktoza hidrat, povidon, umrežena karmelozanatrij, magnezijev stearat.
- CYP3A4 inducers 
- Induktori CYP3A4
Do not take ellaOne together with another emergency contraceptive pill that contains levonorgestrel. 
ellaOne nemojte uzeti zajedno s drugim hitnim kontracepcijskim tabletama koje sadrže levonorgestrel.
Titanium dioxide (E171) Polysorbate 80 (E433) Iron oxide yellow (E172) Potassium aluminium silicate (E555) 
(E171), polisorbat 80 (E433), žuti željezov oksid (E172), kalijev aluminijev silikat (E555)
In vivo results show that the administration of ulipristal acetate with a strong CYP3A4 inducer such as rifampicin markedly decreases Cmax and AUC of ulipristal acetate by 90% or more and decreases ulipristal acetate half-life by 2.2-fold corresponding to an approximately 10-fold decrease of ulipristal acetate exposure. 
In vivo rezultati pokazuju da primjena ulipristalacetata s jakim induktorima CYP3A4 kao što je rifampicin značajno smanjuje Cmax i AUC ulipristalacetata za 90% ili više i smanjuje poluvrijeme eliminacije ulipristalacetata za 2,2 puta što približno odgovara smanjenju izlaganja ulipristalacetatu za 10 puta.
The carton contains one blister. 
Kutija sadrži jedan blister.
Contraception after ellaOne intake 
Kontracepcija nakon uzimanja ellaOne
Concomitant use of ulipristal acetate and emergency contraception containing levonorgestrel is not recommended (see section 4.5). 
Ne preporučuje se istovremeno uzimanje ulipristalacetata i hitne kontracepcije koja sadrži levonorgestrel (vidjeti dio 4.5).
ellaOne is available in a carton containing one blister of 1 film-coated tablet. 
ellaOne je dostupna u kutiji koja sadrži jedan blister s 1 filmom obloženom tabletom.
If you are pregnant, it is important that you see your doctor. 
Ako ste trudni, važno je otići kod liječnika.
The terminal half-life of ulipristal acetate in plasma following a single 30 mg dose is estimated to 32.4 ± 6.3 hours, with a mean oral clearance (CL/F) of 76.8 ± 64.0 L/h. 
Terminalni poluvijek ulipristalacetata u plazmi nakon primjene pojedinačne doze od 30 mg procjenjuje se na 32,4 ± 6,3 sata, uz srednju vrijednost oralnog klirensa (CL/F) od 76,8 ± 64,0 L/h.
Limited and inconclusive data from clinical trials suggest a possible trend for a reduced contraceptive efficacy of ulipristal acetate with high body weight or BMI (see section 4.4). 
Ograničeni podaci iz kliničkih ispitivanja koji ne dopuštaju donošenje konačnih zaključaka ukazuju na mogući trend smanjenja kontracepcijske djelotvornosti ulipristalacetata u žena velike tjelesne težine ili s visokim ITM-om (vidjeti dio 4.4).
The effects of ulipristal acetate on BCRP are unlikely to have any clinical consequences. 
Nije vjerojatno da učinci ulipristalacetata na BCRP imaju ikakve kliničke posljedice.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/. 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu.
For example: - if you had sex without protection; - if your or your partner's condom tore, slipped or came off, or if you forgot to use one; - if you did not take your contraceptive pill as recommended. 
• ako se Vaš ili kondom Vašeg partnera ošteti, sklizne, ispadne ili ga zaboravite uporabiti;
Use in women with severe asthma treated by oral glucocorticoid is not recommended. 
Ne preporučuje se primjena u žena s teškim oblikom astme koje se liječe oralnim glukokortikoidima.
Ulipristal acetate n=34 
Ulipristalacetat n=34
Skin lesion Pruritus 
Kožne lezije Svrbež
Golden film-coated tablet of shield shape (around 10,8 mm diameter) with “ella” engraved on both sides. 
Filmom obložena tableta zlatne boje u obliku štita (promjera približno 10,8 mm) s utisnutom oznakom „ella“ na obje strane.
If you experience these symptoms, do not drive or use machines ellaOne contains lactose 
Ako primijetite ove simptome, nemojte upravljati vozilima ili strojevima.
Ulipristal acetate is a lipophilic compound and is distributed in breast milk, with a mean daily excretion of 13.35 µg [0-24 hours], 2.16 µg [24-48 hours], 1.06 µg [48-72 hours], 0.58 µg [72-96 hours], and 0.31 µg [96-120 hours]. 
Ulipristalacetat je lipofilna tvar i izlučuje se u majčino mlijeko u prosječnim dnevnim količinama od 13,35 μg [0 - 24 sata], 2,16 μg [24 - 48 sati], 1,06 μg [48 - 72 sata], 058 μg [72 - 96 sati], 0,31 μg [96 - 120 sati].
After single dose administration induction of CYP1A2 and CYP3A4 by ulipristal acetate or its active metabolite is not likely. 
Nakon primjene pojedinačne doze nije vjerojatna indukcija CYP1A2 i CYP3A4 ulipristalacetatom ili njegovim aktivnim metabolitom.
Take one tablet as soon as possible after unprotected sex or contraceptive failure. 
Uzmite jednu tabletu što prije nakon nezaštićenog snošaja ili zatajenja kontracepcijske metode.
Your doctor may prescribe another type of (non-hormonal) emergency contraceptive, i.e. a Cu-IUD. 
Vaš liječnik Vam može propisati drugu vrstu (nehormonskog) hitnog kontraceptiva, tj.
Following oral administration of a single 30 mg dose, ulipristal acetate is rapidly absorbed, with a peak plasma concentration of 176 ± 89 ng/ml occurring approximately 1 hour (0.5-2.0 h) after ingestion, and with an AUC0-∞ of 556 ± 260 ng.h/ml. 
Primijenjen peroralno u jednokratnoj dozi od 30 mg, ulipristalacetat se brzo apsorbira dostižući vršnu koncentraciju u plazmi od 176 ± 89 ng/ml oko 1 sat (0,5-2,0 h) nakon ingestije, s AUC0-∞ od 556 ± 260 ng.h/ml.
p<0.005* 
n=8 p<0,005*
(See section “Pregnancy, breast-feeding and fertility”) 
(Pogledajte dio „Trudnoća, dojenje i plodnost“).